Jove
Visualize
Contact Us

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K
Lineage Commitment01:21

Lineage Commitment

3.9K
Commitment is the  process whereby stem cells:
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudo-Richter transformation in a patient with chronic lymphocytic leukemia after cessation of fixed duration venetoclax/ibrutinib treatment.

Annals of hematology·2026
Same author

Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.

Swiss medical weekly·2025
Same author

Successful treatment with Tislelizumab and Zanubrutinib in a patient with relapsed/refractory, CD19/CD20 negative Richter's transformed CLL.

Bone marrow transplantation·2025
Same author

IGLV3-21<sup>R110</sup>-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.

Haematologica·2025
Same author

Busulfan Once Versus Four Times Daily: Impact on Pharmacokinetics, Organ Toxicities and Survival After Allogeneic Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2025
Same author

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.

Blood·2025
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 26, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.5K

[Chronic myeloid leukemia - update 2020].

Dominik Heim1, Monika Ebnöther2, Geneviève Favre3

  • 1Hämatologie, Universitätsspital Basel.

Therapeutische Umschau. Revue Therapeutique
|March 12, 2020
PubMed
Summary
This summary is machine-generated.

Tyrosine kinase inhibitors have transformed chronic myeloid leukemia (CML) treatment, improving patient outcomes. Ongoing research refines these therapies, including molecular monitoring and treatment-free remission strategies for CML management.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K

Related Experiment Videos

Last Updated: Dec 26, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.5K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • The advent of BCR-ABL tyrosine kinase inhibitors has revolutionized chronic myeloid leukemia (CML) treatment.
  • Significant improvements in patient prognosis and outcomes have been observed with these targeted therapies.

Purpose of the Study:

  • To provide an update on the current management of CML in 2020.
  • To discuss advancements in tyrosine kinase inhibitor (TKI) therapy, molecular monitoring, and treatment strategies.

Main Methods:

  • Review of clinical trials and therapeutic advancements in CML management.
  • Analysis of the efficacy and adverse event profiles of first-generation (imatinib) versus second-generation TKIs.
  • Emphasis on standardized molecular methods for assessing treatment response and residual disease.

Main Results:

  • Second-generation TKIs achieve faster and deeper molecular remissions compared to imatinib.
  • Established definitions for optimal response and treatment failure guide patient management.
  • Treatment-free remission is now a viable management option for select CML patients.

Conclusions:

  • Tyrosine kinase inhibitors continue to be the cornerstone of CML therapy, with ongoing refinements.
  • Regular molecular monitoring is crucial for optimizing treatment and assessing response.
  • Allogeneic transplantation remains important for managing advanced CML stages.